Skip to main content
Springer Nature Link
Log in

miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma

  • Original Article
  • Published:
Tumor Biology

Abstract

MicroRNAs (miRNAs) are a new class of prognostic and diagnostic biomarkers for many cancers. Recent studies have shown that miRNAs are highly stable in plasma/serum. The aim of this study was to investigate the role of miR-421 in osteosarcoma. We found that the serum expression levels of miR-421 were significantly higher in osteosarcoma patients than those in healthy volunteers. Moreover, miR-421 expression was significantly higher in osteosarcoma tissues compared with that in the adjacent normal tissues. Meanwhile, the expression of miR-421 was upregulated in 90 % (36/40) osteosarcoma tissues compared to non-tumor tissues. More importantly, the expression levels of miR-421 in osteosarcoma tissues were correlated with those in patients’ serum. In addition, patients with high miR-421 expression had shorter overall survival (OS) than those with low expressions. We also found that overexpression of miR-421 promoted osteosarcoma cell line MG-63 proliferation, migration, and invasion. In conclusion, miR-421 expression levels were upregulated in osteosarcoma tissue and serum and it may be a useful marker for diagnosis of osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Tang J, Shen L, Yang Q, Zhang C. Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition. Cell Prolif. 2014;47(5):427–34. doi:10.1111/cpr.12129.

    Article  CAS  PubMed  Google Scholar 

  2. Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ, Tang CH. CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d. Oncotarget. 2014;5(11):3800–12.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PloS One. 2013;8(1):e53906. doi:10.1371/journal.pone.0053906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PloS One. 2012;7(3):e33778. doi:10.1371/journal.pone.0033778.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PloS One. 2012;7(10):e48086. doi:10.1371/journal.pone.0048086.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012;72(7):1865–77. doi:10.1158/0008-5472.CAN-11-2663.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105(7):755–62. doi:10.1111/cas.12436.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Li Y, Zhang J, Zhang L, Si M, Yin H, Li J. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling. Carcinogenesis. 2013;34(7):1601–10. doi:10.1093/carcin/bgt065.

    Article  CAS  PubMed  Google Scholar 

  9. Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation. 2012;126(7):840–50. doi:10.1161/CIRCULATIONAHA.112.094524.

    Article  CAS  PubMed  Google Scholar 

  10. Martinez-Pacheco M, Hidalgo-Miranda A, Romero-Cordoba S, Valverde M, Rojas E. MRNA and miRNA expression patterns associated to pathways linked to metal mixture health effects. Gene. 2014;533(2):508–14. doi:10.1016/j.gene.2013.09.049.

    Article  CAS  PubMed  Google Scholar 

  11. Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, et al. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatol. 2009;49(4):1194–202. doi:10.1002/hep.22757.

    Article  CAS  Google Scholar 

  12. Yu L, Ding GF, He C, Sun L, Jiang Y, Zhu L. MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb. PloS One. 2014;9(3):e91661. doi:10.1371/journal.pone.0091661.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015. doi: 10.1111/cpr.12180.

  14. Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing’s sarcoma. Cell Prolif. 2015;48(1):1–6. doi:10.1111/cpr.12160.

    Article  PubMed  Google Scholar 

  15. Yu X, Li Z, Liu J. MiRNAs in primary cutaneous lymphomas. Cell Prolif. 2015. doi: 10.1111/cpr.12179.

  16. Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt Pathway by Targeting HOXD10 in intervetebral Disc Degeneration. PloS One. 2013;8(12):e83080. doi:10.1371/journal.pone.0083080.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif. 2012;45(1):32–8. doi:10.1111/j.1365-2184.2011.00798.x.

    Article  CAS  PubMed  Google Scholar 

  18. Li M, Yu M, Liu C, Zhu H, He X, Peng S, et al. miR-34c works downstream of p53 leading to dairy goat male germline stem-cell (mGSCs) apoptosis. Cell Prolif. 2013;46(2):223–31. doi:10.1111/cpr.12013.

    Article  CAS  PubMed  Google Scholar 

  19. Fu LL, Zhao X, Xu HL, Wen X, Wang SY, Liu B, et al. Identification of microRNA-regulated autophagic pathways in plant lectin-induced cancer cell death. Cell Prolif. 2012;45(5):477–85. doi:10.1111/j.1365-2184.2012.00840.x.

    Article  CAS  PubMed  Google Scholar 

  20. Luo X, Dong Z, Chen Y, Yang L, Lai D. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 2013;46(4):436–46. doi:10.1111/cpr.12038.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang WH, Gui JH, Wang CZ, Chang Q, Xu SP, Cai CH, et al. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol Res. 2012;20(4):139–47.

    Article  CAS  PubMed  Google Scholar 

  22. Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, et al. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2013;21(2):83–91. doi:10.3727/096504013X13775486749218.

    Article  PubMed  Google Scholar 

  23. Zhou J, Song S, Cen J, Zhu D, Li D, Zhang Z. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncol Res. 2012;20(5-6):197–203.

    Article  CAS  PubMed  Google Scholar 

  24. Xiao X, Tang C, Xiao S, Fu C, Yu P. Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res. 2013;20(11):537–44. doi:10.3727/096504013X13775486749335.

    Article  CAS  PubMed  Google Scholar 

  25. Kulkarni S, Augoff K, Rivera L, McCue B, Khoury T, Groman A, et al. Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer. PloS One. 2012;7(8):e42895. doi:10.1371/journal.pone.0042895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PloS One. 2012;7(3):e34546. doi:10.1371/journal.pone.0034546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ma R, Yan W, Zhang G, Lv H, Liu Z, Fang F, et al. Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. PloS One. 2012;7(6):e38096. doi:10.1371/journal.pone.0038096.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Hock JM, et al. MiR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer Res. 2014;12(1):101–10. doi:10.1158/1541-7786.MCR-13-0136.

    Article  CAS  PubMed  Google Scholar 

  29. Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp Neurol. 2012;235(2):491–6. doi:10.1016/j.expneurol.2011.11.026.

    Article  CAS  PubMed  Google Scholar 

  30. Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Report. 2012;5(6):1514–20. doi:10.3892/mmr.2012.828.

    CAS  Google Scholar 

  31. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59. doi:10.1093/jnci/djt101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Gao Y, Luo LH, Li S, Yang C. miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochem Biophys Res Commun. 2014;444(2):230–4. doi:10.1016/j.bbrc.2014.01.061.

    Article  CAS  PubMed  Google Scholar 

  33. Lei P, Xie J, Wang L, Yang X, Dai Z, Hu Y. microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1. Mol Med Rep. 2014;10(1):155–60. doi:10.3892/mmr.2014.2195.

    CAS  PubMed  Google Scholar 

  34. Huang YZ, Zhang J, Shao HY, Chen JP, Zhao HY. MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. doi: 10.1007/s13277-015-3290-9.

  35. Zhang Y, Duan G, Feng S. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun. 2015;459(3):367–73. doi:10.1016/j.bbrc.2015.02.101.

    Article  CAS  PubMed  Google Scholar 

  36. Chen L, Tang Y, Wang J, Yan Z, Xu R. miR-421 induces cell proliferation and apoptosis resistance in human nasopharyngeal carcinoma via downregulation of FOXO4. Biochem Biophys Res Commun. 2013;435(4):745–50. doi:10.1016/j.bbrc.2013.05.056.

    Article  CAS  PubMed  Google Scholar 

  37. Wu JH, Yao YL, Gu T, Wang ZY, Pu XY, Sun WW, et al. MiR-421 regulates apoptosis of BGC-823 gastric cancer cells by targeting caspase-3. Asian Pac J Cancer Prev. 2014;15(13):5463–8.

    Article  PubMed  Google Scholar 

  38. Jiang Z, Guo J, Xiao B, Miao Y, Huang R, Li D, et al. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol. 2010;45(1):17–23. doi:10.1007/s00535-009-0135-6.

    Article  CAS  PubMed  Google Scholar 

  39. Hao J, Zhang S, Zhou Y, Liu C, Hu X, Shao C. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Biochem Biophys Res Commun. 2011;406(4):552–7. doi:10.1016/j.bbrc.2011.02.086.

    Article  CAS  PubMed  Google Scholar 

  40. Wu J, Li G, Yao Y, Wang Z, Sun W, Wang J. MicroRNA-421 is a new potential diagnosis biomarker with higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in gastric cancer. Biomarker. 2015;20(1):58–63. doi:10.3109/1354750X.2014.992812.

    Article  CAS  Google Scholar 

  41. Cai H, Zhao H, Tang J, Wu H. Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. J Surg Res. 2015;194(2):505–10. doi:10.1016/j.jss.2014.11.025.

    Article  CAS  PubMed  Google Scholar 

  42. Zhang C, Yao C, Li H, Wang G, He X. Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma. Int J Clin Exp Pathol. 2014;7(7):4194–203.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. Journal of translational medicine. 2012;10:55. doi:10.1186/1479-5876-10-55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Zhou L, Zhao YP, Liu WJ, Dong J, Chen WY, Zhang TP, et al. Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev Anticancer Ther. 2012;12(2):283–8. doi:10.1586/era.11.197.

    Article  CAS  PubMed  Google Scholar 

  45. Hong Q, Fang J, Pang Y, Zheng J. Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol. 2014;31(8):37. doi:10.1007/s12032-014-0037-1.

    Article  PubMed  Google Scholar 

  46. Yuan J, Chen L, Chen X, Sun W, Zhou X. Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 2012;40(6):2090–7.

    Article  CAS  PubMed  Google Scholar 

  47. Wang RJ, Zheng YH, Wang P, Zhang JZ. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(1):765–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Zhao FL, Hu GD, Wang XF, Zhang XH, Zhang YK, Yu ZS. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J Int Med Res. 2012;40(3):859–66.

    Article  CAS  PubMed  Google Scholar 

  49. Faltejskova P, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula R, et al. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. 2012;12(4):199–204. doi:10.3233/CBM-130308.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Spine Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China

    Shuguang Zhou, Bing Wang, Jun Hu & Yucheng Zhou

  2. Department of Orthopedics, The Affiliated Hospital of Hunan University of Medicine and The Third People’s Hospital of Huaihua, Huaihua, 418000, Hunan, China

    Shuguang Zhou, Mingyu Wu & Liming Qin

  3. Department of Orthopedics, The First Hospital of Kunming, Kunming, 650011, Yunnan, China

    Jun Hu

  4. Department of Orthopedics, The People’s Hospital of Qingyuan, Qingyuan, 511518, Guangdong, China

    Yucheng Zhou

  5. Department of Gastroenterology, The Affiliated Hospital of Hunan University of Medicine, Huaihua, 418000, Hunan, China

    Mengzhen Jiang

  6. Department of Spine Surgery, Yan’an Hospital of Kunming, Kunming, 650051, Yunnan, China

    Xuming Yang

Authors
  1. Shuguang Zhou
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Bing Wang
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Jun Hu
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Yucheng Zhou
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Mengzhen Jiang
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Mingyu Wu
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Liming Qin
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Xuming Yang
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Bing Wang.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 13 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, S., Wang, B., Hu, J. et al. miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma. Tumor Biol. 37, 9001–9007 (2016). https://doi.org/10.1007/s13277-015-4578-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4578-5

Keywords